Overall, we found that in most HNSCC models tested, trametinib treatment induced hyperactivation of the PI3K/AKT pathway and that blocking PI3K signaling has a synergistic antitumor effect when combined with trametinib. This evidence concerns the gene AKT1 and head and neck squamous cell carcinoma.